Radiopharm Entered into an Agreement with Lantheus for the Development of NM-01
Shots:
- The companies collaborated on the development of NM-01 which can be labeled with radioisotopes for multiple tumor types. Both the companies get the option to expand the collaboration on additional assets along with license rights in Radiopharm's pipeline
- Lantheus retains an exclusive imaging right to NM-01 (Ex- China) & initiated the P-II trial of NM-01 in NSCLC. The P-I therapeutic trial will be initiated in Australia for PD-L1 + NSCLC
- Both the companies will cross-reference their data to advance PD-L1 assets, incl. the development & regulatory process with the US FDA & other regulatory agencies. Under a separate agreement with NanoMab, Radiopharm gets imaging rights of NM-01 in China & global IP rights for therapeutic use
Ref: PR Newswire | Image: Radiopharm
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
